Kurt Herpel, CEO of Delta4, and Revital Rattenbach, CEO of 4P-Pharma, celebrating the signature of a partnership agreement between Delta4 and 4P-Pharma in Paris (France).

4P-Pharma and Delta4 join forces to find and develop treatments for a rare autoimmune chronic liver disease

Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available.

Contributing to this collaboration, Delta4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signaling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta4’s and 4P-Pharma’s team aim to bring an innovative drug candidate to patients affected by this rare disease.

“4P-Pharma aims to bring breakthrough curative solutions with a strong scientific rationale to patients”, stated Revital Rattenbach, CEO of 4P-Pharma. “With this partnership, we will benefit from Delta4’s AI proprietary computational analytics platform to identify breakthrough drug candidates. Combined with our drug development expertise, together, we will accelerate the identification of drug candidates for patients affected by this rare liver disease. It underlines our shared commitment to bring breakthrough solutions to patients.”

“We are looking forward to joining forces with 4P Pharma to make a difference for patients who are suffering from a devastating disease”, commented Kurt Herpel, CEO, Delta4. Herpel added: “4P-Pharma has consistently proven the viability of their rigorous and focused approach to advancing promising drug candidates up the development pipeline. Specifically, we are excited about the opportunity to apply our platform to a new disease area and to work with 4P-Pharma to make a difference in the treatment of these liver impaired patients.”

About 4P-Pharma

4P-Pharma is a French clinical stage company founded in 2014, dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases. We aim to develop innovative programs with strong scientific rationale, sourced from the top academic research labs and AI based biotechs. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P-Pharma is the dual leverage of in-house R&D capabilities located within Pasteur Institute of Lille (France), combined with single product vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.


About Delta4

Delta4 is a digital drug discovery and development company, focusing on the discovery of novel indications for approved drugs. Delta4 combines in-silico drug discovery and big data analysis with extensive expertise in molecular biology and bioinformatics to a powerful proprietary drug discovery platform. Delta4 uses this platform for the discovery of promising drug leads. The drug leads thus generated are backed by a strong mechanistic hypothesis that significantly reduces the time to a clinical proof-of-concept of validated compounds.


4P-Pharma press contact

Roselina Lam, Business Development and Licensing-in Manager


Delta4 press contact

Kurt Herpel, CEO


Pictured: Kurt Herpel, CEO of Delta4, and Revital Rattenbach, CEO of 4P-Pharma, celebrating the signature of a partnership agreement between Delta4 and 4P-Pharma in Paris (France).